Winfried ELIS,Seth Alexander ETTENBERG,Andrew Paul GARNER,Nicole HAUBST,Xizhong HUANG,Christian Carsten Silvester KUNZ,Elizabeth Anne REISINGER SPRAGUE,Qing SHENG
申请号：
US16115330
公开号：
US20190216924A1
申请日:
2018.08.28
申请国别(地区):
US
年份:
2019
代理人:
摘要：
This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction； and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
